PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Last updated: March 10, 2026
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Recruiting

Phase

2

Condition

Cervical Cancer

Uterine Disorders

Vaginal Cancer

Treatment

Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)

Clinical Study ID

NCT05758688
UPCC 27822
852760
27822
  • Ages > 18
  • Female

Study Summary

This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed cervical or endometrial cancer

  • Indication for adjuvant whole pelvic radiation therapy, with or without systemictherapy

  • Age of 18 years or older

  • Written informed consent

  • ECOG of 0-2 within 3 months of enrolling

Exclusion

Exclusion Criteria:

  • Prior course of pelvic radiation

  • Metastatic disease outside of the pelvis

  • Active inflammatory bowel disease

  • Incapacity to provide informed consent

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)
Phase: 2
Study Start date:
November 06, 2023
Estimated Completion Date:
November 30, 2026

Study Description

This is a single institution, multi-site study, and thus will include patients from geographic locations with Penn proton centers in the Philadelphia, Lancaster and South New Jersey area. The study will be conducted at the University of Pennsylvania Department of Radiation Oncology and associated Clinical facilities.

The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions.

Connect with a study center

  • Virtua Health

    Voorhees, New Jersey 08043
    United States

    Site Not Available

  • Virtua Health

    Voorhees Township, New Jersey 08043
    United States

    Active - Recruiting

  • Lancaster General Health - Ann B. Barshinger Cancer Institute

    Lancaster, Pennsylvania 17601
    United States

    Active - Recruiting

  • Penn Medicine

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.